- Peanuts are the most common fatal allergic reaction of food origin in the United States and other Western countries.
- Sensitization to peanuts may confer greater risk for allergic reaction upon subsequent and continued consumption, however, a large percentage of patients with sensitization do not experience allergic symptoms.
- The Vibrant Peanut Allergy Component test can definitively answer whether your patient has or is at risk for mild, moderate, or severe peanut allergies. This can eliminate doubt and aid in rapid dietary modifications for allergy management.
- Peanut allergy component testing may be ordered with the Vibrant Peanut Zoomer in order to test for the full spectrum of reactivity to peanuts – from mild sensitivity to severe high risk anaphylaxis. The Vibrant Peanut Allergy Component test covers all IgE reactions to peanuts, while the Vibrant Peanut Zoomer covers IgG and IgA reactions, which are less severe, but can still produce uncomfortable symptoms in sensitive patients.
Symptoms and Risk Factors Associated with Peanut Allergy Include:
- Individuals with a history of peanut sensitivity or with documented sensitization by blood or skin prick testing
- Individuals with one or more immediate family members with documented peanut allergy or sensitization
- Redness or swelling of the lips, mouth, throat, or airways after consumption of peanut-containing foods
- Hives after consuming peanuts
- Anaphylaxis after consuming peanut-containing foods
- The Peanut Allergy Component can be run on just one simple blood draw.
- Because the Vibrant Peanut Allergy Component test uses a small amount of blood from the patient, there is no need to expose a high risk patient to a food that may cause allergy, through skin prick or food challenges.
- Ara h 1, 2, 3, 6, 8, and 9 are considered the most important markers of peanut sensitization and are predictive of an allergic response.
What is the difference between the Peanut Component Allergy test and the Peanut Zoomer?
The Vibrant Peanut Component Allergy test is a screen for allergic reactions or allergic sensitization to peanut peptides and components, which involve IgE antibodies to the measured peptides.
The Vibrant Peanut Zoomer is a test for sensitivity to peanut component peptides, which involve IgG and IgA antibodies, and which are not allergic sensitivities.
We recommend running both tests in order to detect the most possible reactions to peanuts in all immunoglobulin (Ig) arms of the immune system.
My Peanut Component Allergy test shows positive antibodies to peanut, but I do not experience any symptoms when I consume peanuts. Is my test wrong?
Many patients have been sensitized to peanuts, which means an initial exposure has triggered the production of IgE (allergy specific) antibodies to this food. These antibodies can be detected in the blood of sensitized individuals. However, because of many variables, antibodies do not always correlate with symptoms and not all peanut component peptides are associated with anaphylaxis or severe, life-threatening allergies. Because of this, you may have elevated antibodies on the Peanut Component Allergy panel, but may not be highly allergic yet. Your healthcare provider will aid you in interpretation of results in conjunction with your symptoms and medical history.
Can I run the Peanut Component Allergy panel in pediatrics?
Yes. While Vibrant has not created reference ranges specific to pediatric populations, this test can and should be run in pediatric populations that are at risk for or suspected of having peanut allergies or sensitization.
The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. This test has been laboratory developed and its performance characteristics determined by Vibrant America LLC, a CLIA-certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.